Summary: Multiple DAA Treatment Failures (All Genotypes), Including Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir Plus Glecaprevir/Pibrentasvir
Recommended regimens listed by evidence level and alphabetically for:
Sofosbuvir/Velpatasvir/Voxilaprevir Treatment Failures, With or Without Compensated Cirrhosisa 
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) plus daily sofosbuvir (400 mg) and weight-based ribavirin
|
16 weeksb
|
IIa, B
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) plus weight-based ribavirin
|
24 weeks
|
IIa, B
|
a For decompensated cirrhosis, please refer to the appropriate section.
b Extension of treatment to 24 weeks should be considered in extremely difficult cases (e.g., genotype 3 with cirrhosis) or failure following sofosbuvir plus glecaprevir/pibrentasvir.
|
